Payment overview · 2025
General Payments
$159.03
8 reported records · 7 companies
Healthcare provider profile · identity verified
Billy J Cole, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · BECKLEY, WV · NPI 1336233626
Verified facts
What the public records show
CMS Open Payments records show Billy J Cole, D.O. received $159.03 in general payments during 2025 across 8 reported records.
Tonix Medicines, Inc. accounted for 30.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Linzess, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 225 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $47.98 | 30.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.73 | 14.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.16 | 12.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.70 | 11.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.67 | 11.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.20 | 10.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.59 | 9.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $159.03 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $47.98 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.16 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 149 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 225 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
70 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
76 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
225 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
149 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 638 | 163 |
| Levothyroxine Sodium | Levothyroxine Sodium | 545 | 133 |
| Gabapentin | Gabapentin | 498 | 90 |
| Furosemide | Furosemide | 436 | 132 |
| Omeprazole | Omeprazole | 431 | 107 |
| Amlodipine Besylate | Amlodipine Besylate | 380 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 375 | 95 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 370 | 104 |
| Pantoprazole Sodium | Pantoprazole Sodium | 362 | 105 |
| Lisinopril | Lisinopril | 326 | 85 |
| Tramadol Hcl | Tramadol Hcl | 276 | 51 |
| Lorazepam | Lorazepam | 264 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 249 | 63 |
| Metformin Hcl | Metformin Hcl | 243 | 64 |
| Ozempic | Semaglutide | 225 | 37 |
| Potassium Chloride | Potassium Chloride | 215 | 73 |
| Methylprednisolone | Methylprednisolone | 212 | 139 |
| Glimepiride | Glimepiride | 202 | 57 |
| Celecoxib | Celecoxib | 191 | 51 |
| Simvastatin | Simvastatin | 191 | 38 |
| Meloxicam | Meloxicam | 190 | 56 |
| Montelukast Sodium | Montelukast Sodium | 188 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 186 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 184 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 181 | 55 |
| Losartan Potassium | Losartan Potassium | 167 | 49 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 163 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 156 | 39 |
| Eliquis | Apixaban | 149 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 146 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 143 | 44 |
| Valsartan | Valsartan | 143 | 48 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 140 | 32 |
| Metformin Hcl Er | Metformin Hcl | 138 | 34 |
| Famotidine | Famotidine | 135 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 132 | 38 |
| Alprazolam | Alprazolam | 119 | 17 |
| Baclofen | Baclofen | 117 | 39 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 114 | 34 |
| Carvedilol | Carvedilol | 113 | 22 |
| Donepezil Hcl | Donepezil Hcl | 105 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 103 | 29 |
| Azithromycin | Azithromycin | 99 | 68 |
| Cefdinir | Cefdinir | 97 | 62 |
| Trazodone Hcl | Trazodone Hcl | 97 | 28 |
| Ondansetron Odt | Ondansetron | 94 | 36 |
| Pregabalin | Pregabalin | 92 | 14 |
| Xarelto | Rivaroxaban | 92 | 22 |
| Ezetimibe | Ezetimibe | 88 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 88 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 87 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 86 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 86 | 17 |
| Atenolol | Atenolol | 83 | 25 |
| Ibuprofen | Ibuprofen | 82 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 80 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 19 |
| Januvia | Sitagliptin Phosphate | 78 | 17 |
| Fenofibrate | Fenofibrate | 77 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 21 |
| Trulicity | Dulaglutide | 76 | 12 |
| Spironolactone | Spironolactone | 75 | 20 |
| Clobetasol Propionate | Clobetasol Propionate | 74 | 25 |
| Memantine Hcl | Memantine Hcl | 74 | suppressed |
| Jardiance | Empagliflozin | 73 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 73 | 20 |
| Diazepam | Diazepam | 72 | 11 |
| Allopurinol | Allopurinol | 71 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 71 | 22 |
| Synthroid | Levothyroxine Sodium | 70 | 19 |
| Levofloxacin | Levofloxacin | 69 | 45 |
| Glipizide Er | Glipizide | 65 | 16 |
| Meclizine Hcl | Meclizine Hcl | 65 | 24 |
| Sertraline Hcl | Sertraline Hcl | 64 | 21 |
| Clonazepam | Clonazepam | 63 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 62 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 39 |
| Fluconazole | Fluconazole | 60 | 28 |
| Naproxen | Naproxen | 60 | 14 |
| Prednisone | Prednisone | 57 | 20 |
| Testosterone Cypionate | Testosterone Cypionate | 57 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 56 | 15 |
| Novolog Flexpen | Insulin Aspart | 56 | 16 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 56 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 52 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 13 |
| Clonidine Hcl | Clonidine Hcl | 49 | 19 |
| Glipizide | Glipizide | 49 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 47 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 47 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 39 |
| Ranolazine Er | Ranolazine | 46 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 45 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | 12 |
| Valacyclovir | Valacyclovir Hcl | 45 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 43 | 13 |
| Finasteride | Finasteride | 41 | 14 |
| Promethazine Hcl | Promethazine Hcl | 41 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 41 | 13 |
| Metolazone | Metolazone | 40 | 15 |
| Bupropion Xl | Bupropion Hcl | 39 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 37 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | suppressed |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Nitroglycerin | Nitroglycerin | 36 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 33 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 33 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 33 | suppressed |
| Estradiol | Estradiol | 33 | suppressed |
| Cilostazol | Cilostazol | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 22 |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Primidone | Primidone | 31 | suppressed |
| Ibu | Ibuprofen | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Lactulose | Lactulose | 29 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Brilinta | Ticagrelor | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 16 |
| Entresto | Sacubitril/Valsartan | 28 | 11 |
| Lovastatin | Lovastatin | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 23 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 20 |
| Dutasteride | Dutasteride | 26 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 22 | 17 |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 14 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 17 |
| Modafinil | Modafinil | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Minoxidil | Minoxidil | 17 | suppressed |
| Nystatin | Nystatin | 17 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Enbrel | Etanercept | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Klayesta | Nystatin | 12 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $159.03 · 8 records | Tonix Medicines, Inc. | Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 2, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, TONMYA | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error